We sat down with Ravi Sharma, Chief Group Pharmacy Officer at Burjeel Holdings, for a compelling conversation on the evolving role of biosimilars in modern healthcare.

From distinguishing biosimilars vs. generics, to addressing confidence gaps and discussing the future of Ustekinumab for Crohn’s disease, Ravi shares strategic insights rooted in both policy and practice.

🔹 What pharmacy leaders must prioritize
🔹 How to overcome adoption barriers with physicians and patients
🔹 A real-world biosimilar success story
🔹 The expected impact of Ustekinumab biosimilars in managing Crohn’s disease
🔹 Cost sustainability and regional access

Tune in for a practical and visionary look at how biosimilars are reshaping the future of care.